Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific internal transaction rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of the notional investment held within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs). On October 11, 2013, an increase in the notional allocation of ADSs occurred at a price of $49.80 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: October 11, 2013.
- Transaction Price: $49.80 per ADS.
- Involved Parties: Dr. M. Slaoui (Director/PDMR) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs; Dr. K. Slaoui received an allocation of 4 ADSs.
- Context: The transaction resulted from a revaluation of the cash element within the GSK 401K plan.